Skip to main content

Omnicell Value Stock - Dividend - Research Selection

Omnicell

ISIN: US68213N1090 , WKN: 632313

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Omnicell, Inc. (NASDAQ:OMCL) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

2025-09-05
Omnicell's (NASDAQ:OMCL) stock is up by a considerable 8.6% over the past month. However, we decided to pay attention...

3 Low-Volatility Stocks We Steer Clear Of

2025-09-05
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

Omnicell (OMCL): Buy, Sell, or Hold Post Q2 Earnings?

2025-09-01
Over the past six months, Omnicell’s stock price fell to $32.30. Shareholders have lost 14.4% of their capital, which is disappointing considering the S&P 500 has climbed by 10.5%. This may have investors wondering how to approach the situation.

Q2 Earnings Highlights: Omnicell (NASDAQ:OMCL) Vs The Rest Of The Healthcare Technology for Providers Stocks

2025-08-28
Looking back on healthcare technology for providers stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Omnicell (NASDAQ:OMCL) and its peers.

Earnings Estimates Rising for Omnicell (OMCL): Will It Gain?

2025-08-26
Omnicell (OMCL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Wall Street Analysts Believe Omnicell (OMCL) Could Rally 34.18%: Here's is How to Trade

2025-08-26
The consensus price target hints at a 34.2% upside potential for Omnicell (OMCL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship

2025-08-26
Separately Secures Access to OneGI Through Brentwood Pharmacy Agreement Gimoti Specialty Pharmacy Network to Almost Double with Additional Relationships SOLANA BEACH, Calif. and CHICAGO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on developing treatments for gastrointestinal (GI) diseases, with a particular emphasis on GIMOTI® (metoclopramide) nasal spray, together with EVERSANA, a leading provider of global commercial services

Omnicell Appoints Baird Radford as Executive Vice President and Chief Financial Officer

2025-08-25
FORT WORTH, Texas, August 25, 2025--Omnicell Appoints Baird Radford as Executive Vice President and Chief Financial Officer

2 Profitable Stocks Worth Investigating and 1 Facing Challenges

2025-08-25
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Pharmacy Automation Company Evaluation Report 2025 | BD, Omnicell, and Capsa Healthcare Lead in Medical Technology, Pharmacy Automation, and Medication Management Solutions

2025-08-14
The Pharmacy Automation Companies Quadrant by MarketsandMarkets 360 provides an essential analysis of the global pharmacy automation market, spotlighting top 20 leaders among 190 evaluated companies. This sector is rapidly advancing from basic pill dispensers to AI-driven systems, driven by demands for precision and efficiency. Key players include BD, Omnicell, and Capsa Healthcare, who are pioneering innovations to optimize medication management and reduce human errors. With growth fueled by fa